Lexaria Bioscience Corp

NASDAQ:LEXXUnited States

Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company's patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting more effective oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. It is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its primary research programs are the investigation of optimal formulations of DehydraTECH-enhanced glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) drugs as well as the investigation of cannabidiol (CBD) for the reduction of hypertension leading to a cleared IND application by the United States Food and Drug Administration. It operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 46 patents granted and many patents pending worldwide.

Contact Information

Headquarters

100 - 740 MCCURDY ROADKELOWNA, BC, Canada V1X 2P7

Phone

250-765-6424

Fax

604-685-7602

Executives

Chairman of the Board

Christopher Bunka

President, Director

John Docherty

Chief Executive Officer

Richard Christopher

Chief Financial Officer

Michael Shankman

Independent Director

Nicholas Baxter